Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

Shelley Wood

February 27, 2023

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

L.A. McKeown

April 04, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

L.A. McKeown

May 21, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

L.A. McKeown

April 02, 2020

Presentation ACC 2020

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Presenter: William Hiatt

March 29, 2020

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

L.A. McKeown

March 28, 2020

Presentation ACC 2018

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

Presenter: Mehdi H. Shishehbor

March 12, 2018

News Conference News ACC 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

Todd Neale

March 12, 2018

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

Advertisement

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

What’s Going to Be Hot at ACC/WCC 2023?

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

COMPASS Approach Helps With Leg Complications in Patients With PAD

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content